$28.00
00.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Immunovant
IMVTNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Immunovant (NASDAQ:IMVT) Stock, Analyst Ratings, Price Targets, Forecasts
Immunovant Inc has a consensus price target of $40 based on the ratings of 21 analysts. The high is $57 issued by Piper Sandler on October 24, 2023. The low is $4 issued by Credit Suisse on May 23, 2023. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and Oppenheimer on June 3, 2024, May 30, 2024, and March 28, 2024, respectively. With an average price target of $49 between Oppenheimer, HC Wainwright & Co., and Oppenheimer, there's an implied 75.00% upside for Immunovant Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Truist Securities
Goldman Sachs
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Immunovant
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 06/03/2024 | Buy Now | 64.29% | Oppenheimer | Leland Gershell | $50 → $46 | Maintains | Outperform | Get Alert |
| 05/30/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 05/30/2024 | Buy Now | 82.14% | HC Wainwright & Co. | Douglas Tsao | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 78.57% | Oppenheimer | Leland Gershell | → $50 | Initiates | → Outperform | Get Alert |
| 03/25/2024 | Buy Now | 71.43% | Truist Securities | Robyn Karnauskas | → $48 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | 78.57% | Goldman Sachs | Corinne Johnson | → $50 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | 82.14% | JP Morgan | Brian Cheng | → $51 | Initiates | → Overweight | Get Alert |
| 02/15/2024 | Buy Now | 96.43% | Wolfe Research | Andy Chen | → $55 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | Buy Now | 82.14% | B of A Securities | Jason Gerberry | $49 → $51 | Maintains | Buy | Get Alert |
| 12/21/2023 | Buy Now | 82.14% | HC Wainwright & Co. | Douglas Tsao | $47 → $51 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 78.57% | Deutsche Bank | Neena Bitritto-Garg | → $50 | Initiates | → Buy | Get Alert |
| 12/01/2023 | Buy Now | 100% | UBS | Colin Bristow | $55 → $56 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 71.43% | Truist Securities | Robyn Karnauskas | $30 → $48 | Maintains | Buy | Get Alert |
| 10/24/2023 | Buy Now | 103.57% | Piper Sandler | Yasmeen Rahimi | $28 → $57 | Maintains | Overweight | Get Alert |
| 10/24/2023 | Buy Now | 67.86% | HC Wainwright & Co. | Douglas Tsao | $29 → $47 | Maintains | Buy | Get Alert |
| 10/16/2023 | Buy Now | 60.71% | Cantor Fitzgerald | Louise Chen | $30 → $45 | Maintains | Overweight | Get Alert |
| 10/13/2023 | Buy Now | 96.43% | UBS | Colin Bristow | $18 → $55 | Upgrade | Neutral → Buy | Get Alert |
| 10/09/2023 | Buy Now | 7.14% | Cantor Fitzgerald | Louise Chen | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | Buy Now | 71.43% | Wells Fargo | Derek Archila | $33 → $48 | Maintains | Overweight | Get Alert |
| 09/27/2023 | Buy Now | 78.57% | Citigroup | Samantha Semenkow | $33 → $50 | Maintains | Buy | Get Alert |
| 09/27/2023 | Buy Now | 42.86% | Raymond James | Danielle Brill | → $40 | Upgrade | Market Perform → Outperform | Get Alert |
| 09/26/2023 | Buy Now | 7.14% | Truist Securities | Robyn Karnauskas | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | 14.29% | Guggenheim | Yatin Suneja | → $32 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | 7.14% | Cantor Fitzgerald | Louise Chen | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 7.14% | Cantor Fitzgerald | Louise Chen | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2023 | Buy Now | 7.14% | Truist Securities | Robyn Karnauskas | → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 3.57% | HC Wainwright & Co. | Douglas Tsao | → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 17.86% | Citigroup | Samantha Semenkow | $28 → $33 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 17.86% | Wells Fargo | Derek Archila | $27 → $33 | Maintains | Overweight | Get Alert |
| 07/18/2023 | Buy Now | 21.43% | Stifel | Alex Thompson | $28 → $34 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 3.57% | HC Wainwright & Co. | Douglas Tsao | $27 → $29 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -3.57% | HC Wainwright & Co. | Douglas Tsao | $26 → $27 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | — | B of A Securities | Jason Gerberry | $26 → $28 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 14.29% | Guggenheim | Yatin Suneja | $30 → $32 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -85.71% | Credit Suisse | Tiago Fauth | → $4 | Reiterates | → Underperform | Get Alert |
| 05/23/2023 | Buy Now | 14.29% | Chardan Capital | Matthew Barcus | $21 → $32 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | -7.14% | B of A Securities | Jason Gerberry | → $26 | Initiates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | — | Citigroup | Samantha Semenkow | → $28 | Initiates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | — | Piper Sandler | Yasmeen Rahimi | → $28 | Initiates | → Overweight | Get Alert |
| 03/30/2023 | Buy Now | — | Stifel | Alex Thompson | → $28 | Initiates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | -7.14% | HC Wainwright & Co. | Douglas Tsao | $21 → $26 | Maintains | Buy | Get Alert |
| 02/15/2023 | Buy Now | 7.14% | Cantor Fitzgerald | Louise Chen | → $30 | Initiates | → Overweight | Get Alert |
| 02/13/2023 | Buy Now | — | Guggenheim | Yatin Suneja | — | Upgrade | Neutral → Buy | Get Alert |
| 02/07/2023 | Buy Now | -25% | HC Wainwright & Co. | Douglas Tsao | $17 → $21 | Maintains | Buy | Get Alert |
| 02/06/2023 | Buy Now | -25% | SVB Leerink | Thomas Smith | $14 → $21 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | -25% | Chardan Capital | Matthew Barcus | $19 → $21 | Maintains | Buy | Get Alert |
| 01/03/2023 | Buy Now | -3.57% | Wells Fargo | Derek Archila | $10 → $27 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/08/2022 | Buy Now | -64.29% | Wells Fargo | Derek Archila | $7 → $10 | Maintains | Equal-Weight | Get Alert |
| 11/07/2022 | Buy Now | -39.29% | HC Wainwright & Co. | Douglas Tsao | $16 → $17 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | -32.14% | Chardan Capital | Matthew Barcus | $12 → $19 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | -50% | SVB Leerink | Mike Kratky | $12 → $14 | Maintains | Outperform | Get Alert |
| 09/29/2022 | Buy Now | -57.14% | Chardan Capital | Matthew Barcus | $14 → $12 | Maintains | Buy | Get Alert |
| 09/26/2022 | Buy Now | -82.14% | UBS | Colin Bristow | $7 → $5 | Downgrade | Buy → Neutral | Get Alert |
| 12/08/2021 | Buy Now | -67.86% | Wells Fargo | Derek Archila | — | Initiates | → Equal-Weight | Get Alert |
| 11/08/2021 | Buy Now | -42.86% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
| 08/03/2021 | Buy Now | -64.29% | Baird | Brian Skorney | — | Downgrade | Outperform → Neutral | Get Alert |
FAQ
What is the target price for Immunovant (IMVT) stock?
The latest price target for Immunovant (NASDAQ:IMVT) was reported by Cantor Fitzgerald on June 20, 2024. The analyst firm set a price target for $0.00 expecting IMVT to fall to within 12 months (a possible -100.00% downside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunovant (IMVT)?
The latest analyst rating for Immunovant (NASDAQ:IMVT) was provided by Cantor Fitzgerald, and Immunovant reiterated their overweight rating.
When was the last upgrade for Immunovant (IMVT)?
The last upgrade for Immunovant Inc happened on October 13, 2023 when UBS raised their price target to $55. UBS previously had a neutral for Immunovant Inc.
When was the last downgrade for Immunovant (IMVT)?
The last downgrade for Immunovant Inc happened on September 26, 2022 when UBS changed their price target from $7 to $5 for Immunovant Inc.
When is the next analyst rating going to be posted or updated for Immunovant (IMVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunovant, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunovant was filed on June 20, 2024 so you should expect the next rating to be made available sometime around June 20, 2025.
Is the Analyst Rating Immunovant (IMVT) correct?
While ratings are subjective and will change, the latest Immunovant (IMVT) rating was a reiterated with a price target of $0.00 to $0.00. The current price Immunovant (IMVT) is trading at is $28.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.